Comment by catigula
7 days ago
These psychedelic treatments always have substantial limitations, and this is no different;
1. Low volume cohort i.e. 40 participants per dose group
2. Industry sponsored study i.e. MindMed.
3. Think about it; how do you blind psychedelics? It's pretty obvious you're on one when you take it.
I recall an experiment where the control group was given Ritalin, and the participants had presumably tried neither Ritalin or the psychedelic.
I thought it was pretty cool, since the control group will still "feel" something and potentially think "oh this is it" but since the effects of stimulants like Ritalin have been more studied, the researchers can easily account for it.
Let me guess: Those limitations are ”unscientific” in this context, but when the article is about the dangers of cannabis, they are suddenly okay?
This isn't unscientific per se, it's just low quality science. No conclusions should be drawn. There are known treatments with extremely robust, good science.